학술논문
Study protocol: Minimum effective low dose: Anti-human thymocyte globulin (MELD-ATG): Phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes
Document Type
Article
Author
Wilhelm-Benartzi, C.S.; Mander, A.; Miller, S.E.; Bruggraber, S.; Picton, D.; Wilson, M.; Marcovecchio, M.L.; Hendriks, A.E.J.; Dunger, D.; Gatley, K.; Bond, S.; Chhabra, A.; Morobé, H.; Overbergh, L.; Mathieu, C.; Chmura, P.J.; Aschemeier-Fuchs, B.; Knip, M.; Tree, T.; Pall, J.; Arnaud, O.; Haller, M.J.; Nitsche, A.; Schulte, A.M.
Source
In: BMJ Open . (BMJ Open, 7 December 2021, 11(12))
Subject
Language
English
ISSN
20446055